Small Molecule Orphan Drugs: Status Quo, Challenges, and Perspectives
Summary: When deciding on the right partner, considering their experience in working with orphan-designated products is key. A collaborative, free-flowing and communicative partnership can ensure the originator’s and patients’ needs are met. In this article, experts discuss the key drivers that motivate drug sponsors in developing orphan drugs. In addition, experts explore the challenges of orphan drug development and manufacturing and will discuss how the industry is leveraging strategic partnerships to help mitigate these challenges to create a viable orphan drug business model.